Drugs / NP000888
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02995473 | Feb 2017 → May 2018 | psoriasis | Galderma R&D | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP000888 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02995473 ↗ |
| Route | Topical | “270 µg/g topical (BID) for 24 weeks” NCT02995473 ↗ |